Skip to main content

Scholar Rock Holding

Scholar Rock Holding Corp is an American clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines targeting muscle and bone diseases. The company utilizes its proprietary discovery platform to target growth factor activation mechanisms, specifically focusing on myostatin inhibition for rare and severe conditions. Its leading clinical pipeline candidate is apitegromab, being evaluated for the treatment of spinal muscular atrophy and other neuromuscular disorders. Core operations encompass preclinical drug design, protein engineering, clinical trial management, and biotechnology research. As a development-stage biopharmaceutical entity, the company generates minimal commercial revenue and relies on equity financing and research partnerships. Scholar Rock is headquartered in Cambridge, Massachusetts, United States, and its common stock trades on the Nasdaq Global Market.

7 of the funds FundTelligence covers report a position in Scholar Rock Holding.

Legal name
Scholar Rock Holding Corp
Sector
Health Care
Country
United States
Funds holding it
7

Funds holding Scholar Rock Holding

Loading...